Zenas BioPharma to present at upcoming Healthcare investor conferences. September 04, 2026 07:05 ET | Source: Zenas BioPharma WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) - Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management's presentations at the following investor conferences: * Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ET * Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET * H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 8:00 a.m. ET Live webcasts and archived replays of the Company's presentations can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib's mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas' earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

Zenas BioPharma (NASDAQ:ZBIO) stock price down 6.6% on disappointing earnings. August 13, 2026 Key points. * Zenas BioPharma shares fell 6.6% after the company reported quarterly EPS of $(1.77), missing the $(1.12) consensus estimate, while revenue of $1 million was far below the $15 million forecast. * Despite the earnings miss, analysts maintain a generally positive outlook: six rate the stock a Buy, two a Hold and one a Sell, producing a "Moderate Buy" consensus and an average price target of $44.29. * CEO Leon O. Moulder Jr. purchased 60,000 shares for roughly $1.01 million, increasing his direct ownership by 162.5%; insiders collectively own 22% of the company. * Five stocks we like better than Zenas BioPharma. Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) shares dropped 6.6% on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $28.01 and last traded at $29.2150. 129,747 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 834,254 shares. The stock had previously closed at $31.29. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $15.00 million. Wall Street analysts forecast growth. Several research firms have recently issued reports on ZBIO. Wall Street Zen raised shares of Zenas BioPharma from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 27th. Morgan Stanley lifted their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an "equal weight" rating in a research note on Thursday, May 14th. Citigroup reiterated a "buy" rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. HC Wainwright restated a "buy" rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Zacks Research raised Zenas BioPharma from a "strong sell" rating to a "hold" rating in a report on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $44.29. Insider buying and selling. In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the firm's stock in a transaction on Monday, May 18th. The shares were acquired at an average cost of $16.88 per share, for a total transaction of $1,012,800.00. Following the purchase, the chief executive officer directly owned 96,928 shares of the company's stock, valued at $1,636,144.64. The trade was a 162.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.00% of the stock is currently owned by insiders. Institutional inflows and outflows. Several institutional investors have recently modified their holdings of ZBIO. SR One Capital Management LP lifted its position in Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company's stock valued at $182,924,000 after purchasing an additional 126,315 shares during the last quarter. NEA Management Company LLC increased its holdings in shares of Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company's stock worth $127,928,000 after buying an additional 789,500 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company's stock valued at $98,603,000 after buying an additional 853,740 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Zenas BioPharma during the 2nd quarter valued at $68,176,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company's stock worth $52,761,000 after acquiring an additional 290,307 shares during the last quarter. Zenas BioPharma price performance. The company has a market capitalization of $1.83 billion, a PE ratio of -3.43 and a beta of -1.03. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The firm's 50-day moving average is $26.49 and its 200-day moving average is $23.27. Zenas BioPharma company profile. Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns. Discover more Cryptocurrency market data Track Market Trends Financial News Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Zenas BioPharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list. While Zenas BioPharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Zenas BioPharma CEO Leon O. Moulder Jr. purchased 60,000 shares at a weighted average price of $16.88, totalling approximately $1 million, according to an SEC Form 4 filing. The transaction brings his directly-held shares to 423,155, with total beneficial ownership exceeding 520,000 shares, or roughly 0.95% of outstanding shares. The purchase falls within the higher end of Moulder's transaction sizes over the past year, which have ranged from 54,000 to 100,000 shares, indicating sustained accumulation. The shares were acquired whilst the stock showed a 53.6% one-year total return. Zenas BioPharma, a clinical-stage biopharmaceutical company, develops immunology-based therapies targeting autoimmune and inflammatory diseases. The company reported a net loss of $425.15 million over the trailing twelve months and holds a market capitalisation of $846.87 million.